Info

HemoGenix® was the first company in the world to provide contract hemotoxicity testing service as its primary work. This was started when HemoGenix® came into being in June 2000. Since that time, HemoGenix® has become the leader in stem cell toxicity testing using its own proprietary in vitro, cell-based and non-invasive platforms. Whereas others may offer subjective, non-standardized and even non-validated assays with limited population and species comparison ability and no high-throughput capability, such as the 40 year old colony-forming assay, HemoGenix® has single-handedly brought stem cell hemotoxicity testing into the 21st century with its HALO® Platform. We have provided our contract services to small, medium and some of the largest biotechnology and pharmaceutical companies in the world. In addition, we also work with academic and clinical centers. HALO® (Hematopoietic / Hemotoxicity Assays via Luminescence Output) is a unique assay platform that was originally developed to improve throughput of potential drug candidates and the ability to predict potential toxicity to the lympho-hematopoietic system at any stage in the drug discovery and drug development pipeline, from screening to patient monitoring during clinical trials. The HALO® Platform was designed to use primary human hematopoietic tissues (fresh bone marrow, peripheral blood and umbilical cord blood), but HemoGenix® has developed HALO® so that it can be employed for any primary animal species used in pre-clinical testing, namely non-human primate, dog, rat and mouse. The HALO® Platform offers predictive, cost-effective hemotoxicity testing which, if implemented early in drug discovery, i.e. ADME/Tox screening, can save significant time, money and animal testing dowstream and improve safety and potential risk to the patient. The HALO® Platform has been validated against the Registry of Cytotoxicity Prediction Model and is therefore a validated cytotoxicity assay. We have developed a unique prediction paradigm that allows toxicity to the blood-forming system to be predicted on the basis of how specific cell populations respond to agents. In addition, the prediction paradigm can be used to estimate dosing for pre-clinical animal studies and even human clinical dosing. Besides drug discovery and development applications, our platforms are also capable of testing virtually any agent using fresh primary human or animal tissue or cell lines. For this we have developed 2 other in vitro platforms, LUMENESCÔ for cells of the Mesenchymal Stem Cell System and LumiSTEMÔ for all other cells that exhibit proliferation characteristics. Together, the 3 Platforms, HALO®, LUMENESCÔ and LumiSTEMÔ constitute the HemoGenix® "In Vitro Cross-Platform Comparative Toxicity" Testing Procedure with which more than 50 cell types from 14 different cell systems can be analyzed simultaneously using a single, standardized ATP-based bioluminescence technology that allows all result to be directly compared, thereby allowing compounds and other agents to be ranked in order of toxicity and their potential organismic effects predicted. The ATP-based bioluminescence signal detection system provides information on 4 cellular parameters simultaneously.